Archives of Clinical Infectious Diseases

Published by: Kowsar

Approaches to Treat Patients Infected With Multi-Drug-Resistant Acinetobacter baumannii

Masoud Mardani 1 , *
Author Information
1 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • Archives of Clinical Infectious Diseases: December 24, 2012, 8 (1); 1-2
  • Published Online: December 24, 2012
  • Article Type: Editorial
  • Received: November 6, 2012
  • Accepted: November 25, 2012
  • DOI: 10.5812/archcid.16252

To Cite: Mardani M. Approaches to Treat Patients Infected With Multi-Drug-Resistant Acinetobacter baumannii, Arch Clin Infect Dis. 2012 ; 8(1):1-2. doi: 10.5812/archcid.16252.

Copyright © 2012, Infectious Diseases and Tropical Medicine Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnotes
References
  • 1. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 2008; 13(47)[PubMed]
  • 2. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 2008; 13(47)[PubMed]
  • 3. Towner KJ. Acinetobacter: an old friend, but a new enemy. J Hosp Infect. 2009; 73(4): 355-63[DOI][PubMed]
  • 4. Mishra SK, Rijal BP, Pokhrel BM. Emerging threat of multidrug resistant bugs--Acinetobacter calcoaceticus baumannii complex and methicillin resistant Staphylococcus aureus. BMC Res Notes. 2013; 6: 98[DOI][PubMed]
  • 5. Falagas ME, Bliziotis IA, Tam VH. Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence. Int J Antimicrob Agents. 2007; 29(1): 9-25[DOI][PubMed]
  • 6. Levin AS, Gobara S, Mendes CM, Cursino MR, Sinto S. Environmental contamination by multidrug-resistant Acinetobacter baumannii in an intensive care unit. Infect Control Hosp Epidemiol. 2001; 22(11): 717-20[DOI][PubMed]
  • 7. Popovic M, Steinort D, Pillai S, Joukhadar C. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis. 2010; 29(2): 127-42[DOI][PubMed]
  • 8. Dellit TH, Owens RC, McGowan JE, Jr, Gerding DN, Weinstein RA, Burke JP, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44(2): 159-77[DOI][PubMed]
  • 9. Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother. 2009; 53(8): 3430-6[DOI][PubMed]
  • 10. Li J, Nation RL, Turnidge JD, Milne RW, Coulthard K, Rayner CR, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis. 2006; 6(9): 589-601[DOI][PubMed]
  • 11. Cunha BA. Pharmacokinetic considerations regarding tigecycline for multidrug-resistant (MDR) Klebsiella pneumoniae or MDR Acinetobacter baumannii urosepsis. J Clin Microbiol. 2009; 47(5): 1613[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .
Readers' Comments